After training initially with one of the top biotech patent groups in the U.S. and practicing in large general practice firms for over 20 years, Carl has the experience to meet the intellectual property needs of startups, mid-size R&D companies, large biotherapeutic and pharmaceutical companies, and top tier, research-intensive universities. He enjoys doing single-project work, as well as comprehensive counseling and portfolio development for startups and growing companies.
Carl counsels scientific founders on initial protection strategies for their platform technology (timing, scope of disclosure, landscape analysis, ownership issues), develops licensing programs for biotechnology, and evaluates lifecycle management programs for marketed human therapeutics. He also has evaluated patent and patent litigation issues involving biotechnology, pharmaceuticals, as well as manufacturing and energy technology, including mechanical and chemical areas. Carl assists clients at every stage of the business lifecycle, from discovery, through development and commercialization.
Carl’s experience allows him to add value as a trusted member of the business team for his clients, and not merely as a hired legal technician.
Boston University School of Law, J.D. (1997)
Duke University, M.S., Biochemistry (1994)
University of Alabama, Birmingham, M.S., Biology
Wake Forest University, B.S., Biology (1986)
U.S. Patent and Trademark Office (1998)
North Carolina (1999)
West District of North Carolina (2014)
Fourth Circuit Court of Appeals
Prior Work Experience
Sterne, Kessler, Goldstein & Fox, PLLC (1997-1999)
Kilpatrick Stockton, LLP (now Kilpatrick Townsend) (1999-2001)
Womble Bond Dickinson (US) LLP (2001-2019)